S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00661193
Completed
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving erlotinib together with carboplatin and paclitaxel may kill more tumor cells. PURPOSE: This randomized phase II trial is studying how well erlotinib works when given alone or together with carbop... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
02/19/2020
Locations: Harrington Cancer Center, Amarillo, Texas
Conditions: Lung Cancer
Register for Updates
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
NCT00006227
Completed
This phase II trial studies the effectiveness of paclitaxel in treating patients who have ovarian stromal cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
Gender:
FEMALE
Ages:
All
Trial Updated:
02/18/2020
Locations: Brooke Army Medical Center, Fort Sam Houston, Texas +1 locations
Conditions: Adult Type Ovarian Granulosa Cell Tumor, Ovarian Gynandroblastoma, Ovarian Sertoli-Leydig Cell Tumor, Ovarian Sex Cord Tumor With Annular Tubules, Ovarian Steroid Cell Tumor
Register for Updates
PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation
NCT01402063
Completed
To obtain preliminary data in a randomized phase II study whether PPX/RT improves progression-free survival as compared to temozolomide/RT for patients with GBM without MGMT methylation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2020
Locations: UT Southwestern Cancer Center, Dallas, Texas
Conditions: Glioblastoma Multiforme
Register for Updates
A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies
NCT02327169
Completed
The primary purpose of this study is to determine the safety profile and the maximum tolerated doses (MTDs)/ potential recommended phase 2 doses (RP2Ds) of the combination treatments of MLN2480 + MLN0128, MLN2480 + alisertib, MLN2480 + paclitaxel, MLN2480 + cetuximab, and MLN2480 + irinotecan in participants with advanced nonhematologic malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2020
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Nonhematologic Malignancies
Register for Updates
A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer
NCT02117024
Terminated
Determine whether viagenpumatucel-L combined with low-dose cyclophosphamide prolongs survival in patients with NSCLC who failed 2 or 3 prior lines of therapy for incurable or metastatic disease compared with chemotherapy alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2020
Locations: Texas Oncology PA Texas Cancer Center, Abilene, Texas +1 locations
Conditions: Non Small Cell Lung Cancer
Register for Updates
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
NCT02383212
Completed
This is a phase 1, open-label, multicenter, ascending-dose escalation study of cemiplimab, alone and in combination with other anti-cancer therapies in patients with advanced malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/23/2020
Locations: Mary Crowley Cancer Research Center - Medical City, Dallas, Texas +3 locations
Conditions: Advanced Cancer, Advanced Malignancies
Register for Updates
Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas
NCT01730586
Completed
The goal of this clinical research study is to learn if abraxane can help to control colorectal and/or small bowel cancer. The safety of this drug will also be studied. Abraxane is designed to block cancer cells from dividing, which may cause them to die.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2020
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Colorectal Cancer, Cancer of Gastrointestinal Tract
Register for Updates
TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
NCT00563784
Completed
The goal of this clinical research study is to find out if erlotinib given with chemotherapy and radiation therapy can help to control NSCLC. The safety of this combination treatment will also be studied. Researchers will also test the tissue from your earlier biopsy to measure the levels of epidermal growth factor receptor (EGFR). The purpose of EGFR testing is to learn about any link between various forms of EGFR and your response to treatment with erlotinib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2019
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Non-Small Cell Lung Cancer, Lung Cancer
Register for Updates
ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer
NCT00394082
Completed
The purpose of this study is to evaluate the safety and tolerability of weekly ABI-007 in combination with bevacizumab. The evaluation of progression-free survival of weekly ABI-007 in combination with bevacizumab for patients with previously untreated advanced/metastatic breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/13/2019
Locations: Not set, Bedford, Texas +5 locations
Conditions: Metastatic Breast Cancer
Register for Updates
Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer
NCT00093145
Completed
This trial will treat patients with advanced breast cancer with a new anti-cancer medicine used in combination with two existing anti-cancer medications: Albumin-bound paclitaxel (ABI-007), Carboplatin and Herceptin. Participants will be given the combination therapy on a weekly basis and may continue on therapy as long as their condition improves and drug toxicity is tolerated.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/13/2019
Locations: Southwest Regional Cancer Center, Austin, Texas
Conditions: Breast Cancer
Register for Updates
Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer
NCT00281528
Terminated
This is a multi-center, open-label, randomized Phase II study in previously untreated patients with metastatic breast cancer to evaluate the antitumor activity and safety of weekly dose-dense ABI-007 (Abraxane) compared to 2-weekly regimen vs the standard 3-weekly infusion. All patients will also receive concurrent bevacizumab.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/07/2019
Locations: TX Oncology, PA, Austin, Texas +1 locations
Conditions: Breast Neoplasms, Neoplasm Metastasis
Register for Updates
Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer
NCT00394251
Completed
The primary objective of this study was to compare the safety of dose-dense ABI-007 (Abraxane) 260 mg/m\^2 or Taxol 175 mg/m\^2 given every 2 weeks following dose-dense Adriamycin plus Cytoxan (AC) chemotherapy. Bevacizumab was administered at 10 mg/kg every 2 weeks throughout chemotherapy, and then at 15 mg/kg every 3 weeks following chemotherapy.
Gender:
FEMALE
Ages:
Between 18 years and 70 years
Trial Updated:
11/07/2019
Locations: Not set, Austin, Texas +11 locations
Conditions: Breast Cancer
Register for Updates